Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096688 · ClinicalTrials.gov registry record
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
A clinical trial of Colorectal Cancer and Endometrial Cancer, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- 1,120
- Enrollment target
- 1
- Study location
NCT06096688: Recruiting study of Colorectal Cancer and Endometrial Cancer, sponsored by Weill Medical College of Cornell University.
NCT06096688 is a study of Colorectal Cancer and Endometrial Cancer that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 1,120 participants, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06096688, a study of Colorectal Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- 1,120 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.
Primary Outcome
Discover novel mechanisms in intestinal carcinogenesis and genes inducing genetic predisposition to Hereditary Cancer Syndromes.
Conditions Studied
Study Locations (1)
New York
- NYP/Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,120 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2026-12-31 |
What NCT06096688 shows while recruiting
NCT06096688 is an observational study that tracks outcomes without assigning an intervention. Its 1,120 participants enrollment target places it among the larger protocols in the corpus, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (27% lower).
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06096688 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06096688 about?
NCT06096688 is a clinical study titled "Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction". The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studie...
What is the current status of trial NCT06096688?
This trial is currently recruiting. The enrollment target is 1,120 participants. The study started on 2019-05-29. Estimated completion is 2026-12-31.
What conditions does trial NCT06096688 study?
This clinical trial studies the following conditions: Colorectal Cancer, Endometrial Cancer, Hereditary Cancer Syndromes.
Who is sponsoring clinical trial NCT06096688?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06096688 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06096688's enrollment target sits among peer trials
1,120 44th of 381 higher than 338 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI